However, for isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GBM) patients, molecular targeted treatment has not yet been established, and the overall prognosis of patients with this highly malignant brain tumor remains poor. The gene discussed is IDH3A; the disease is glioblastoma.